Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Entera Bio (ENTX) EBT Margin (2019 - 2025)

Entera Bio has reported EBT Margin over the past 6 years, most recently at 6102.38% for Q1 2025.

  • For the quarter ending Q1 2025, EBT Margin changed N/A year-over-year to 6102.38%, compared with a TTM value of 27419.05% through Dec 2025, down 2211960.0%, and an annual FY2025 reading of 27235.71%, down 2197218.0% over the prior year.
  • EBT Margin came in at 6102.38% for Q1 2025, down from 2858.54% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1471.34% in Q1 2021 to a low of 35912.5% in Q3 2022.
  • Median EBT Margin over the past 4 years was 4686.62% (2022), compared with a mean of 8278.71%.
  • The sharpest move saw EBT Margin skyrocketed 607077bps in 2021, then crashed -3360750bps in 2022.
  • Over 4 years, EBT Margin stood at 2493.94% in 2021, then plummeted by -782bps to 22007.14% in 2022, then soared by 87bps to 2858.54% in 2024, then plummeted by -113bps to 6102.38% in 2025.
  • Per Business Quant, the three most recent readings for ENTX's EBT Margin are 6102.38% (Q1 2025), 2858.54% (Q4 2024), and 7192.86% (Q3 2024).